Credit Suisse Ag Outlook Therapeutics, Inc. Transaction History

Credit Suisse Ag

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.87 - $1.33 $585 - $895	-673 Reduced 99.26%	5 $0
Q3 2022 Nov 10, 2022	BUY	$1.02 - $1.26 $672 - $830	659 Added 3468.42%	678 $1,000
Q2 2022 Aug 12, 2022	BUY	$0.91 - $2.01 $17 - $38	19 New	19 $0
Q3 2020 Nov 13, 2020	SELL	$0.61 - $1.6 $30,500 - $80,000	-50,000 Closed	0 $0
Q2 2020 Aug 12, 2020	BUY	$0.56 - $1.41 $28,000 - $70,500	50,000 New	50,000 $65,000

67.1K

Ticker OTLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,144,992
Market Cap $1.6B
Description
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.